CUL3 — gene · CancerIndex

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CUL3 Mutation + KEAP1 Mutation + NFE2L2 MutationNFE2L2 KEAP1 CUL31
Platinum Doublet	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	2	accepted	EID12558 In a retrospective study of stage IV NSCLC patients treated with first-line platinum doublet chemotherapy (n = 103; 51 KEAP1/NFE2L2/CUL3-mutant, 52 WT), mutations in NFE2L2, KEAP1, or CUL3 were associ… (full text at CIViC) PMID 31548347 · Jeong et al., 2020 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (82)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved82 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Bladder Cancer (Columbia University/MSK, Cell 2018) bladder_columbia_msk_2018	unmapped	Ssm	20	130

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer.
· Clin Cancer Res · 2020 · PMID 31548347 · validated civic_curation pubmed